gbr 12935 has been researched along with Parkinson Disease in 8 studies
1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine : An N-alkylpiperazine that consists of piperazine bearing 2-(benzhydryloxy)ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "[3H]GBR 12935 binding was decreased in the putamen and caudate nucleus of subjects with Parkinson's disease (33 and 46% of control values, respectively) and progressive supranuclear palsy (38 and 57% of control values, respectively)." | 1.27 | [3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. ( Agid, Y; Javoy-Agid, F; Laduron, PM; Laterre, C; Maloteaux, JM; Vanisberg, MA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allard, PO | 1 |
| Rinne, J | 1 |
| Marcusson, JO | 1 |
| Stasi, K | 1 |
| Mitsacos, A | 1 |
| Giompres, P | 1 |
| Kouvelas, ED | 1 |
| Triarhou, LC | 1 |
| Falkenburger, BH | 1 |
| Barstow, KL | 1 |
| Mintz, IM | 1 |
| Niznik, HB | 1 |
| Fogel, EF | 1 |
| Fassos, FF | 1 |
| Seeman, P | 2 |
| Pearce, RK | 1 |
| Jellinger, K | 1 |
| Tourtellotte, WW | 1 |
| Maloteaux, JM | 1 |
| Vanisberg, MA | 1 |
| Laterre, C | 1 |
| Javoy-Agid, F | 1 |
| Agid, Y | 1 |
| Laduron, PM | 1 |
| Hirai, M | 1 |
| Kitamura, N | 1 |
| Hashimoto, T | 1 |
| Nakai, T | 1 |
| Mita, T | 1 |
| Shirakawa, O | 1 |
| Yamadori, T | 1 |
| Amano, T | 1 |
| Noguchi-Kuno, SA | 1 |
| Tanaka, C | 1 |
| Janowsky, A | 1 |
| Vocci, F | 1 |
| Berger, P | 1 |
| Angel, I | 1 |
| Zelnik, N | 1 |
| Kleinman, JE | 1 |
| Skolnick, P | 1 |
| Paul, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials[NCT00354003] | 800 participants (Anticipated) | Observational | 2006-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for gbr 12935 and Parkinson Disease
| Article | Year |
|---|---|
Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Humans; Ligands; Parkinson Disease; Piperazines; Putamen; Receptors, Dopami | 1994 |
Partial restoration of striatal GABAA receptor balance by functional mesencephalic dopaminergic grafts in mice with hereditary parkinsonism.
Topics: Animals; Autoradiography; Brain Tissue Transplantation; Corpus Striatum; Fetal Tissue Transplantatio | 1999 |
Dendrodendritic inhibition through reversal of dopamine transport.
Topics: Animals; Biological Transport; Calcium; Carrier Proteins; Dendrites; Dopamine; Dopamine D2 Receptor | 2001 |
The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.
Topics: Affinity Labels; Aged; Azides; Binding Sites; Binding, Competitive; Carrier Proteins; Caudate Nucleu | 1991 |
Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Binding Sites; Dopamine; Female; Humans; Levodopa; Ligands; Male; Mi | 1990 |
[3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy.
Topics: Animals; Binding Sites; Corpus Striatum; Dopamine; Humans; In Vitro Techniques; Male; Parkinson Dise | 1988 |
[3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics.
Topics: Aged; Animals; Binding Sites; Binding, Competitive; Corpus Striatum; Female; Humans; In Vitro Techni | 1988 |
[3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease.
Topics: Caudate Nucleus; Cell Membrane; Corpus Striatum; Humans; Kinetics; Ligands; Nucleus Accumbens; Parki | 1987 |